Matthew Luchini
Stock Analyst at BMO Capital
(0.70)
# 2,955
Out of 4,667 analysts
50
Total ratings
32.14%
Success rate
-8.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $11.23 | +167.14% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $20.98 | +805.62% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $27.49 | +151.00% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $5.79 | +1,696.20% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $4.05 | +1,258.02% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $22.69 | +345.13% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $743.35 | -15.25% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $317.09 | -60.89% | 2 | Nov 6, 2020 | |
| BLUE bluebird bio | Downgrades: Market Perform | $56 | $0.30 | +18,381.85% | 11 | Nov 5, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $88.63 | -27.79% | 2 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $51.53 | -72.83% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $2.71 | +2,114.02% | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $120 → $164 | $1.40 | +11,642.86% | 5 | Mar 8, 2018 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $11.23
Upside: +167.14%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $20.98
Upside: +805.62%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $27.49
Upside: +151.00%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $5.79
Upside: +1,696.20%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $4.05
Upside: +1,258.02%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $22.69
Upside: +345.13%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $743.35
Upside: -15.25%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $317.09
Upside: -60.89%
bluebird bio
Nov 5, 2020
Downgrades: Market Perform
Price Target: $56
Current: $0.30
Upside: +18,381.85%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $88.63
Upside: -27.79%
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $51.53
Upside: -72.83%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $2.71
Upside: +2,114.02%
Mar 8, 2018
Maintains: Market Perform
Price Target: $120 → $164
Current: $1.40
Upside: +11,642.86%